Elba Medina
@elbaonelida.bsky.social
Nephrologist in Mexico, HGM, #NSMC intership 2024 #NephSky #MedSky #LatinSky #HMSky #Kidneydisease #sunrise #NephJC
Reposted by Elba Medina
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
November 19, 2025 at 2:41 AM
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Reposted by Elba Medina
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
November 19, 2025 at 2:39 AM
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
Reposted by Elba Medina
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
November 19, 2025 at 2:38 AM
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
Reposted by Elba Medina
T2c: #NephJC
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
November 19, 2025 at 2:31 AM
T2c: #NephJC
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
Reposted by Elba Medina
T0h: #NephJC
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
November 19, 2025 at 2:15 AM
T0h: #NephJC
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Although both BAFF and APRIL are responsible for B-cell proliferation, survival/maturation, and class switching they affect different stages of B cell maturation.
www.kidneynews.org/v...
Reposted by Elba Medina
T0i: #NephJC
Mechanistic lead-in came from the JANUS ph2 study (N=16):
👉 dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24
👉maintained through week 72
👍 concurrent proteinuria improvement and preserved eGFR
pubmed.ncbi.nlm.nih....
Mechanistic lead-in came from the JANUS ph2 study (N=16):
👉 dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24
👉maintained through week 72
👍 concurrent proteinuria improvement and preserved eGFR
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:17 AM
T0i: #NephJC
Mechanistic lead-in came from the JANUS ph2 study (N=16):
👉 dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24
👉maintained through week 72
👍 concurrent proteinuria improvement and preserved eGFR
pubmed.ncbi.nlm.nih....
Mechanistic lead-in came from the JANUS ph2 study (N=16):
👉 dose-dependent reductions in IgA, IgG, IgM, and Gd-IgA1 by week 24
👉maintained through week 72
👍 concurrent proteinuria improvement and preserved eGFR
pubmed.ncbi.nlm.nih....
Reposted by Elba Medina
T0j: #NephJC
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:18 AM
T0j: #NephJC
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
Reposted by Elba Medina
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:19 AM
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
Reposted by Elba Medina
🥁 Drum rolls… The ORIGINal saga in IgAN unfolds. Interim chapter at 36 weeks, curtain rises, but the finale will still remain hidden. Moving on to RESULTS next #NephJC
November 19, 2025 at 2:28 AM
🥁 Drum rolls… The ORIGINal saga in IgAN unfolds. Interim chapter at 36 weeks, curtain rises, but the finale will still remain hidden. Moving on to RESULTS next #NephJC
Reposted by Elba Medina
T0d: #NephJC
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:11 AM
T0d: #NephJC
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
Reposted by Elba Medina
T0a: #NephJC
Remember 2021, and the first glomerulonephritis @kdigo.org guidelines for IgAN? Only RASi and steroids were viable treatment options. However, it seems in 2025 we have so many other options, no?
Remember 2021, and the first glomerulonephritis @kdigo.org guidelines for IgAN? Only RASi and steroids were viable treatment options. However, it seems in 2025 we have so many other options, no?
November 19, 2025 at 2:08 AM
T0a: #NephJC
Remember 2021, and the first glomerulonephritis @kdigo.org guidelines for IgAN? Only RASi and steroids were viable treatment options. However, it seems in 2025 we have so many other options, no?
Remember 2021, and the first glomerulonephritis @kdigo.org guidelines for IgAN? Only RASi and steroids were viable treatment options. However, it seems in 2025 we have so many other options, no?
Reposted by Elba Medina
🎨Beautiful visual abstract by @salinesolut.bsky.social
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
www.nephjc.com
November 19, 2025 at 2:05 AM
🎨Beautiful visual abstract by @salinesolut.bsky.social
Reposted by Elba Medina
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 18, 2025 at 12:29 PM
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Reposted by Elba Medina
#Empagliflozin and #Ultrafiltration Volume in Patients Undergoing #PeritonealDialysis
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00624-2/fulltext
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00624-2/fulltext
November 13, 2025 at 12:00 PM
#Empagliflozin and #Ultrafiltration Volume in Patients Undergoing #PeritonealDialysis
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00624-2/fulltext
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00624-2/fulltext
Reposted by Elba Medina
As nephrologists, we tend to focus on pathways, labs, and outcome curves. For years, IgAN meant familiar drugs and modest gains. Reading new guidelines through a patient’s story is a reminder of why it matters #nephjc
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
KDIGO IgA Guidelines: A Patient Voice — NephJC
We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.
www.nephjc.com
October 28, 2025 at 2:28 AM
As nephrologists, we tend to focus on pathways, labs, and outcome curves. For years, IgAN meant familiar drugs and modest gains. Reading new guidelines through a patient’s story is a reminder of why it matters #nephjc
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
Perspective by @jonathanpollack.bsky.social
www.nephjc.com/news/2025/10...
Reposted by Elba Medina
IgA nephropathy: The immune twist behind the Kidney decline!!
Join us today to learn more on the recent (And first ever disease specific) evidence based KDIGO IgA Nephropathy guidelines.
There’s still time to review the highlights before the discussion.
#NephJC
Join us today to learn more on the recent (And first ever disease specific) evidence based KDIGO IgA Nephropathy guidelines.
There’s still time to review the highlights before the discussion.
#NephJC
October 28, 2025 at 11:00 PM
IgA nephropathy: The immune twist behind the Kidney decline!!
Join us today to learn more on the recent (And first ever disease specific) evidence based KDIGO IgA Nephropathy guidelines.
There’s still time to review the highlights before the discussion.
#NephJC
Join us today to learn more on the recent (And first ever disease specific) evidence based KDIGO IgA Nephropathy guidelines.
There’s still time to review the highlights before the discussion.
#NephJC
Reposted by Elba Medina
Great read on ways of measuring renal function. Shout out to @elbaonelida.bsky.social
www.kireportscommunity.org/post/towards...
www.kireportscommunity.org/post/towards...
Towards new ways of assessing kidney function. Where to look to improve?
Written by Elba MedinaReviewed by Brian Rifkin;Sophia AmbrusoToday, current methods for measuring kidney function, due to several critical limitations, need to be reimagined. In the reimagining Kidney...
www.kireportscommunity.org
October 26, 2025 at 2:46 AM
Great read on ways of measuring renal function. Shout out to @elbaonelida.bsky.social
www.kireportscommunity.org/post/towards...
www.kireportscommunity.org/post/towards...
Reposted by Elba Medina
Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky
✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social
www.nephjc.com/news/2025/10...
✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social
www.nephjc.com/news/2025/10...
Empagliflozin, the kidney, and what we still don’t understand — NephJC
NephJC short on an empagliflozin meta-analysis
www.nephjc.com
October 21, 2025 at 9:25 AM
Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky
✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social
www.nephjc.com/news/2025/10...
✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social
www.nephjc.com/news/2025/10...
Reposted by Elba Medina
the filtrate @freelyfiltered.bsky.social listening raptly to Mike Walsh tell us about the events unfolding as ACHIEVE achieved futility
@kidneyboy.bsky.social @medpeedskidneys.bsky.social
#nephsky
@kidneyboy.bsky.social @medpeedskidneys.bsky.social
#nephsky
October 19, 2025 at 6:53 PM
Reposted by Elba Medina
Check out the Spanish VA. #NephSky
Como siempre muchas gracias @dramiliflores.bsky.social
www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual
Como siempre muchas gracias @dramiliflores.bsky.social
www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual
Suplementación con proteínas en la ERC: El Resumen Visual — NephJC
¿La suplementación con proteínas mejora la calidad de vida en la ERC avanzada? Revisa este resumen visual creado por Marc Soco , que sintetiza una nueva revisión sistemática y metanálisis! ¡No olvi...
www.nephjc.com
October 13, 2025 at 1:19 PM
Check out the Spanish VA. #NephSky
Como siempre muchas gracias @dramiliflores.bsky.social
www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual
Como siempre muchas gracias @dramiliflores.bsky.social
www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual
Reposted by Elba Medina
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Protein supplementation in CKD: The Visual Abstract — NephJC
We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?
www.nephjc.com
October 13, 2025 at 1:14 PM
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Reposted by Elba Medina
Up next!
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
October 6, 2025 at 8:29 PM
Up next!
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍
On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC
pubmed.ncbi.nlm.nih.gov/40876553/
#Skytorial by @nephromommy-akshu.bsky.social
Akshaya's signing off 👋
Reposted by Elba Medina
Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘.
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression? — NephJC
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
www.nephjc.com
September 29, 2025 at 1:56 AM
Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘.
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Reposted by Elba Medina
It's that time of year again 🍂🍂🍂
The #NephJC Fall pledge drive.
Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky
www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive
The #NephJC Fall pledge drive.
Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky
www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive
NephJC 2025 Fall Pledge Drive — NephJC
Help keep NephJC a vital, original, and unbiased source of medical education.
www.nephjc.com
September 22, 2025 at 12:47 AM
It's that time of year again 🍂🍂🍂
The #NephJC Fall pledge drive.
Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky
www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive
The #NephJC Fall pledge drive.
Plese give if you are able to support our decades long mission of #FOAMed for all. #NephSky #MedSky
www.nephjc.com/news/2025/9/22/nephjc-fall-pledge-drive